Psoriasis Induced by Trastuzumab (HerceptinⓇ)
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Trastuzumab (Herceptin), a humanized monoclonal antibody,is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such as folliculitis, xerosis, and alopecia have not been reported with therapies targeting HER2, in spite of the frequent observances of such with the therapies targeting the epidermal growth factor receptor. We experienced a patient in whom psoriasis was triggered by the trastuzumab treatment for breast cancer. She was a 57-year-old woman with erythematous and scaly plaques occurring a few months after starting trastuzumab, with repeated aggravation after the re-administration of trastuzumab for the breast cancer. Histologic examination showed the typical features of psoriasis with parakeratosis,epidermal hyperplasia, elongation of the rete ridges, and a lymphocytic and polymorphonuclear cell infiltrate in the dermis. To the best of our knowledge, this is the first report of psoriasis triggered by trastuzumab treatment for breast cancer.
Abstract
Trastuzumab (Herceptin), a humanized monoclonal antibody,is a cancer drug developed to target the human epidermal receptor (HER) 2, which is overexpressed in some cancer cells. Cutaneous side effects, such as folliculitis, xerosis, and alopecia have not been reported with therapies targeting HER2, in spite of the frequent observances of such with the therapies targeting the epidermal growth factor receptor. We experienced a patient in whom psoriasis was triggered by the trastuzumab treatment for breast cancer. She was a 57-year-old woman with erythematous and scaly plaques occurring a few months after starting trastuzumab, with repeated aggravation after the re-administration of trastuzumab for the breast cancer. Histologic examination showed the typical features of psoriasis with parakeratosis,epidermal hyperplasia, elongation of the rete ridges, and a lymphocytic and polymorphonuclear cell infiltrate in the dermis. To the best of our knowledge, this is the first report of psoriasis triggered by trastuzumab treatment for breast cancer.
참고문헌 (8)
- Chang HR, "Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer", Cancer, 116, pp.2856~2867 (2010)
- Garnock-Jones KP, "Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer", Drugs, 70, pp.215~239 (2010)
- Laux I, "Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies", Br J Cancer, 94, pp.85~92 (2006)
- Myskowski PL, "Skin reactions to the new biologic anticancer drugs", Curr Opin Support Palliat Care, 3, pp.294~299 (2009)
- Arteaga C, "Targeting HER1", EGFR: a molecular approach to cancer therapy, 2003, pp.30(3 Suppl 7), 3~14
- Mendelsohn J, "The EGF receptor family as targets for cancer therapy", Oncogene, 19, pp.6550~6565 (2000)
- De Potter IY, "Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation", Exp Cell Res, 271, pp.315~328 (2001)
- Rosman IS, "Tufted hair folliculitis in a woman treated with trastuzumab", Target Oncol, 5, pp.295~296 (2010)